Ludwig Hantson is succeedingAlex Gorsky, who resigned two months ago to rejoin Johnson & Johnson, as ceo of the drugmaker's North American pharma operations, according to a statement sent us by Novartis.
Hantson, 45, who joined Novartis in 2001 from J&J's Janssen division, most recently headed the drugmaker's specialty meds unit and before that he was senior vp for commercial development and specialty business. He also ran operations in Europe and Canada.
Separately, Gary Rosenthal, who has been cfo for Novartis Pharmaceuticals in the US, was named ceo and president of the US corporate holding entity. He succeeds Paulo Costa, who once ran the US pharma biz and is now retiring.